Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase ring finger protein 133 (RNF133) is an enzyme that catalyzes the transfer of ubiquitin from E2 conjugating enzymes to substrate proteins. It is specifically expressed in the testis and is essential for the proper morphological development and motility of sperm cells during spermiogenesis. RNF133 is a membrane-associated protein localized to the endoplasmic reticulum and facilitates selective protein degradation as part of the ER-associated degradation pathway. Loss of RNF133 activity in mice leads to severely reduced sperm fertility, abnormal sperm morphology, and impaired motility, highlighting its critical physiological role in male reproductive biology[1][2][4][5][7]. RNF133 is a member of the RING finger protein family of E3 ligases and interacts with UBE2J1, an ER-localized E2 ubiquitin-conjugating enzyme[1][2][5]. Currently, there are no drugs, established biomarkers, or clinical safety concerns directly linked to RNF133, though its essential role in spermatogenesis makes it a candidate for research in male fertility and contraceptive development.
not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase ring finger protein 133 (RNF133).